Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.

X Ma, Cynthia; J Suman, Vera; Sanati, Souzan; Vij, Kiran; Anurag, Meenakshi; Marilyn Leitch, A; W Unzeitig, Gary; Hoog, Jeremy; Fernandez-Martinez, Aranzazu; Fan, Cheng; A Gibbs, Richard; A Watson, Mark; J Dockter, Travis; Hahn, Olwen; M Guenther, Joseph; Caudle, Abigail; Crouch, Erika; Tiersten, Amy; Mita, Monica; Razaq, Wajeeha; J Hieken, Tina; Wang, Yang; F Rimawi, Mothaffar; Weiss, Anna; P Winer, Eric; K Hunt, Kelly; M Perou, Charles; J Ellis, Matthew; H Partridge, Ann; A Carey, Lisa

doi:10.1001/jamaoncol.2023.6038

Public

Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.

Shared by NobleBlocks on Mar 1, 2024 • 12:00 AM UTC

Authors:

Cynthia X Ma

Vera J Suman

Souzan Sanati

Abstract

Importance: Adding fulvestrant to anastrozole (A+F) improved survival in postmenopausal women with advanced estrogen receptor (ER)-positive/ERBB2 (formerly HER2)-negative breast cancer. However, the combination has not been tested in early-stage disease. Objective: To determine whether neoadjuvant f...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!